Notícias

The day after Moderna’s stock posted its biggest one-day gain on record, it is on track for its largest percent drop in more than two years as investors digested the news and adjusted their positions. Prior to Wednesday’s rally on positive mRNA cancer vaccine data, Moderna’s stock had substantial short interest at 13.7%. UBS said its clients sold a record $44 million in Moderna shares Wednesday, suggesting some investors were cashing out after the rally.

Moderna (MRNA) shares jumped after the company reported positive results from a late-stage trial of its personalized melanoma vaccine. Bernstein senior analyst of US Biopharmaceuticals Courtney Breen joins Julie Hyman on Market Catalysts to break down the trial results, what’s driving the stock move, and the potential pricing opportunity for Moderna’s cancer vaccine.

Hedge funds are quietly loading up on a battered pharma giant while yield hunters circle its once-near-7% dividend, but with a 14% rally already in the books and patent cliffs looming, the real question is whether the smart money spotted a turning point or a trap.

RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.

A historic one-session rally in a cancer vaccine stock is already unwinding, and Wall Street analysts disagree sharply on whether the reversal reflects a trade gone cold or an opportunity that the market is mispricing.

Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

Moderna (MRNA) and Merck (MRK) reported promising results in their melanoma vaccine trial, sending the stocks soaring. BD8 Capital Partners CEO and CIO Barbara Doran and Yahoo Finance Markets and Data Editor Jared Blikre chat with Yahoo Finance Executive Editor Brian Sozzi about what the breakthrough could mean for Pfizer (PFE) and the larger healthcare sector.

RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.

A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.

Stock Market Today: The Dow Jones index drops Thursday on Trump's "Economic D-Day" threat on Iran. Walmart dives on earnings.

Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.

News of the day for Aug. 20, 2026

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Moderna tumbles as investors take some profit following Wednesday’s surge, while crypto stocks rally.

In August 2026, Merck and Moderna reported that their Phase 3 INTerpath-001 trial showed that individualized mRNA therapy intismeran (V940/mRNA-4157) plus KEYTRUDA improved recurrence-free and distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma versus KEYTRUDA alone. This marks the first successful Phase 3 result for both an individualized neoantigen mRNA cancer therapy and an mRNA treatment outperforming a standard-of-care immunotherapy in the...

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Companies In The Article Are:MRNA,MRK,MRVL,GOOG,TGT and LOW

Investing.com -- Moderna shares pulled back sharply on Thursday, giving up a small chunk of Wednesday’s record-breaking rally after the stock rocketed as much as 177% on data showing its personalized cancer vaccine, developed with Merck, slowed the spread and recurrence of melanoma. Merck shares had jumped 12.6% on Wednesday alongside Moderna’s surge.

By Mike Dolan Aug 20 (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-at-Large, Finance and Markets Buybacks to the rescue? The surprising move by the U.S.

Moderna (NASDAQ:MRNA) shares fell sharply in premarket trading on Thursday as investors took profits following the biggest one-day rally in the biotechnology company’s history, while concerns over valuation added to the selling pressure. The stock dropped 13.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

↘️ Coty (COTY): The beauty company reported a steeper loss and guided for a drop in sales in the current quarter. Shares fell over 7% before the bell. ↘️ Moderna (MRNA): Shares pulled back 10% in premarket trading following yesterday’s 177% rally— the biggest gain for any stock in the S&P 500 in the past 25 years.

Wall Street weighs in on a big day for Moderna.

Retail sentiment on Stocktwits remained ‘neutral’ on SPY and QQQ.

The Morning Bull - US Market Morning Update Thursday, Aug, 20 2026 US stock futures are slightly higher this morning, with E mini S&P 500 contracts up about 0.1% and Nasdaq 100 futures ahead around 0.1% to 0.2%. The key driver is the US 10 year Treasury yield holding near 4.75%, which means borrowing costs for mortgages, car loans and corporate debt remain relatively high. At the same time, US housing data is mixed, with building permits rising 5% in July while housing starts fell 12.4%,...

Moderna and Merck's have been highlighted in this Investment Ideas article.

Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.